Results. RBV dose modification due to anaemia were significantly less in combined group (8.5 versus 21.5%.P < .05).Withdrawal, secondary to sever anemia (Hb < 8.5 gm%), was recorded only in 6 (28.6%) patients of the control group. The gene discussed is GSTM1; the disease is anemia.